STERIS walks into its May 6 fiscal Q4 print with short sellers actively retreating — the most telling positioning signal ahead of the release.
Short interest has fallen sharply. SI % of free float dropped from roughly 2% at the start of April to 1.52% now, a decline of nearly 20% over the past month. That unwind accelerated in the final week of April, with shorts cutting positions by 15% in five sessions. Cost to borrow reinforces the picture: at 0.37%, it's edged lower over the week, and availability in the lending pool remains wide open — only a tiny fraction of available shares are currently being lent out. There is no squeeze pressure here, and no sign of a building bear thesis in the derivative lending market.
Options positioning tells a more cautious story, though not an extreme one. The put/call ratio has climbed to 1.30, running well above its 20-day average of 0.95. The z-score of 0.71 keeps this within one standard deviation, so it reads more as moderate defensive hedging than outright fear — especially when measured against the 52-week high PCR of 3.31. The stock itself has drifted lower: down 3.3% on the week and off 3% over the past month to $214.40, giving back ground after trading above $264 earlier this year.
The debate heading into the print centres on capital equipment recovery. The bull case rests on STERIS's demonstrated ability to grow organic revenue — up 5% year-over-year in the prior quarter — and to expand margins, with EBIT improving 110 basis points and EPS rising 14% year-on-year on reduced interest costs following the dental segment divestiture. The bear case focuses on the capital equipment line, where sales fell roughly 16% year-on-year last quarter, service revenues dropped 21%, and the backlog shrank by $66 million. Analysts are broadly constructive — consensus sits at buy, with a mean target around $279, implying roughly 30% upside from current levels. The most recent analyst data (from August 2025) shows Morgan Stanley at Overweight with a $295 target, but that predates the current price weakness and may not fully reflect the capital equipment headwinds that have dominated since.
Past earnings reactions add context. The last two prints produced day-one declines of roughly 5–7%, with five-day losses in the same range — a consistent pattern of post-earnings selling pressure.
The May 6 print is ultimately a test of whether the capital equipment backlog contraction has stabilised, and whether margin progress can offset the volume weakness that has defined the last two quarters.
See the live data behind this article on ORTEX.
Open STE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
